European Association for the Study of the Liver (EASL) clinical practice guidelines on the management of decompensated cirrhosis, including ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome in cirrhosis are available (European Association for the Study of the Liver, 2018).

The progression from compensated to decompensated cirrhosis is marked by numerous overt clinical signs such as ascites, bleeding, encephalopathy, and jaundice. The progression of the disease and the associated complications can reduce median survival from 12 years to approximately 2 years. The need for effective management of these symptoms has led the European Association for the Study of the Liver to publish their first Clinical Practice Guidelines for the management of decompensated cirrhosis. The recommendation of albumin infusion is seen across the guidelines for a number of the complications discussed. This infographic highlights the role of albumin has in managing the signs and symptoms of decompensated cirrhosis.

EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Download a PDF version here.


  • Management of Decompensated Cirrhosis EASL Guideline

    An asymptomatic compensated phase followed by a decompensated phase characterises the natural history of cirrhosis. It is also marked by the development of overt clinical signs. The most frequent of which are ascites, bleeding, encephalopathy, and jaundice. See the Clinical Practice Guideline.


Explore the Fluid Management Knowledge Centre to discover more about the role of fluid therapy in cardiac surgery, critically ill patients, liver cirrhosis, and more.

Have you joined the debate around hydroxyethyl starch? Get up-to-date as we take you on an interactive journey through the ups and downs of its use. Do you think current restrictions will be enough to change clinical practice?